Cholesterol, statins, and dementia: What the cardiologist should know

Brett L. Wanamaker; Kristopher J. Swiger; Roger S. Blumenthal; Seth S. Martin

doi:10.1002/clc.22361

Cholesterol, statins, and dementia: What the cardiologist should know

Brett L. Wanamaker, Kristopher J. Swiger, Roger S. Blumenthal, Seth S. Martin

School of Medicine

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Abstract

Alzheimer dementia (AD) is an important clinical problem that appears to be closely tied to comorbid cardiovascular disease, making it a relevant topic for the clinical cardiologist. Determinants of cardiovascular health, especially midlife dyslipidemia, are associated with an increased risk of dementia based on molecular and epidemiologic data. Given the potential role of dyslipidemia in the development of dementia, statins have been investigated as potential therapeutic options to slow or prevent disease. This review discusses the role of dyslipidemia and other cardiovascular risk factors in the pathogenesis of AD, with a focus on the existing evidence for the use of statin medications in the treatment and prevention of AD from observational studies and randomized clinical trials. Clinical questions for the practicing cardiologist are addressed.

Original language	English (US)
Pages (from-to)	243-250
Number of pages	8
Journal	Clinical Cardiology
Volume	38
Issue number	4
DOIs	https://doi.org/10.1002/clc.22361
State	Published - Apr 1 2015

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/clc.22361

Cite this

@article{f692ed4a4a114cdd98863c1d3c62f0f8,

title = "Cholesterol, statins, and dementia: What the cardiologist should know",

abstract = "Alzheimer dementia (AD) is an important clinical problem that appears to be closely tied to comorbid cardiovascular disease, making it a relevant topic for the clinical cardiologist. Determinants of cardiovascular health, especially midlife dyslipidemia, are associated with an increased risk of dementia based on molecular and epidemiologic data. Given the potential role of dyslipidemia in the development of dementia, statins have been investigated as potential therapeutic options to slow or prevent disease. This review discusses the role of dyslipidemia and other cardiovascular risk factors in the pathogenesis of AD, with a focus on the existing evidence for the use of statin medications in the treatment and prevention of AD from observational studies and randomized clinical trials. Clinical questions for the practicing cardiologist are addressed.",

author = "Wanamaker, {Brett L.} and Swiger, {Kristopher J.} and Blumenthal, {Roger S.} and Martin, {Seth S.}",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2015",

month = apr,

day = "1",

doi = "10.1002/clc.22361",

language = "English (US)",

volume = "38",

pages = "243--250",

journal = "Clinical Cardiology",

issn = "0160-9289",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Cholesterol, statins, and dementia

T2 - What the cardiologist should know

AU - Wanamaker, Brett L.

AU - Swiger, Kristopher J.

AU - Blumenthal, Roger S.

AU - Martin, Seth S.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Alzheimer dementia (AD) is an important clinical problem that appears to be closely tied to comorbid cardiovascular disease, making it a relevant topic for the clinical cardiologist. Determinants of cardiovascular health, especially midlife dyslipidemia, are associated with an increased risk of dementia based on molecular and epidemiologic data. Given the potential role of dyslipidemia in the development of dementia, statins have been investigated as potential therapeutic options to slow or prevent disease. This review discusses the role of dyslipidemia and other cardiovascular risk factors in the pathogenesis of AD, with a focus on the existing evidence for the use of statin medications in the treatment and prevention of AD from observational studies and randomized clinical trials. Clinical questions for the practicing cardiologist are addressed.

AB - Alzheimer dementia (AD) is an important clinical problem that appears to be closely tied to comorbid cardiovascular disease, making it a relevant topic for the clinical cardiologist. Determinants of cardiovascular health, especially midlife dyslipidemia, are associated with an increased risk of dementia based on molecular and epidemiologic data. Given the potential role of dyslipidemia in the development of dementia, statins have been investigated as potential therapeutic options to slow or prevent disease. This review discusses the role of dyslipidemia and other cardiovascular risk factors in the pathogenesis of AD, with a focus on the existing evidence for the use of statin medications in the treatment and prevention of AD from observational studies and randomized clinical trials. Clinical questions for the practicing cardiologist are addressed.

UR - http://www.scopus.com/inward/record.url?scp=84928434453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928434453&partnerID=8YFLogxK

U2 - 10.1002/clc.22361

DO - 10.1002/clc.22361

M3 - Review article

C2 - 25869997

AN - SCOPUS:84928434453

SN - 0160-9289

VL - 38

SP - 243

EP - 250

JO - Clinical Cardiology

JF - Clinical Cardiology

IS - 4

ER -

Cholesterol, statins, and dementia: What the cardiologist should know

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this